1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

SCNI
Scinai Immunotherapeutics Ltd.US flagNASDAQ Capital Market
0.25
USD
+0.01
- -
331,998.00Market Cap

Total Valuation

Scinai Immunotherapeutics Ltd. carries a market capitalization of 331,998.00, placing it among publicly traded companies globally. Its enterprise value stands at 17.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap331,998.00
Enterprise Value17.69M

Share Statistics

Scinai Immunotherapeutics Ltd. currently has 6.06B shares outstanding.

Shares Outstanding6.06B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Scinai Immunotherapeutics Ltd. trades at a trailing price-to-earnings ratio of 2.61. The price-to-sales ratio is 9.32, and the price-to-book ratio stands at -0.09.

PE Ratio2.61
PS Ratio9.32
PB Ratio-0.09
P/TBV Ratio4.79
P/FCF Ratio-1.88
P/OCF Ratio-1.88

Enterprise Valuation

EV / Sales15.42
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Scinai Immunotherapeutics Ltd. maintains a current ratio of 0.71, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.98, indicating elevated leverage, while an interest coverage ratio of -3.51 demonstrates limited ability to service its debt obligations.

Current Ratio0.71
Quick Ratio0.64
Debt / Equity29.98
Debt / EBITDA-0.35
Interest Coverage-3.51

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)30.65
Return on Invested Capital (ROIC)-71.11
Return on Capital Employed (ROCE)-5.47
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Scinai Immunotherapeutics Ltd.'s stock has declined approximately -89.12069% over the past 52 weeks. The 50-day moving average sits at 0.37, while the 200-day moving average is 0.77.

Beta (5Y)N/A
52-Week Price Change-89.12069%
50-Day Moving Average0.37
200-Day Moving Average0.77
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Scinai Immunotherapeutics Ltd. generated 1.15M in revenue and converted that into 4.09M in net income, yielding earnings per share of 2.97. EBITDA reached -6.74M, while operating income came in at -8.45M.

Revenue1.15M
Gross Profit-1.69M
Operating Income-8.45M
Pretax Income4.12M
Net Income4.09M
EBITDA-6.74M
EBIT-8.45M
Earnings Per Share (EPS)2.97

Balance Sheet

Scinai Immunotherapeutics Ltd. holds 989,000.00 in cash and equivalents against 2.36M in total debt, resulting in a net debt position of -696,000.00. Total book value stands at -121.67M, with working capital of -614,000.00 providing operational flexibility.

Cash & Cash Equivalents989,000.00
Total Debt2.36M
Net Debt-696,000.00
Equity (Book Value)-121.67M
Book Value Per Share-87.75
Working Capital-614,000.00

Cash Flow

Scinai Immunotherapeutics Ltd. produced -5.69M in operating cash flow over the past twelve months. After subtracting -16,000.00 in capital expenditures, free cash flow totaled -5.70M - equivalent to -4.11 per share.

Operating Cash Flow-5.69M
Capital Expenditures-16,000.00
Free Cash Flow-5.70M
FCF Per Share-4.11

Margins

Scinai Immunotherapeutics Ltd. operates with a gross margin of -146.99, reflecting its pricing power and cost economics. The operating margin of -736.36 and net profit margin of 356.67 provide insight into operational efficiency.

Gross Margin-146.99
Operating Margin-736.36
Pretax Margin359.02
Profit Margin356.67
EBITDA Margin-588.06

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-33.57
FCF Yield-53.06

Stock Splits

Scinai Immunotherapeutics Ltd.'s most recent stock split took place on May 21, 2024 with a 10:1 split ratio.

Last Split Date5/21/2024
Split Ratio10:1

Scores

Scinai Immunotherapeutics Ltd. posts an Altman Z-Score of -15.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-15.10